Efficacy and Safety of Neurocognitive Adaptive Training for Depression
A 12-Week Study Overview
This study explored how Neurocognitive Adaptive Training for Depression (NCAT-D) works with selective serotonin reuptake inhibitors (SSRIs) to help patients with cognitive issues due to late-life depression (LLD).
Study Details
Conducted from May 5, 2021, to April 21, 2023, at Beijing Anding Hospital, the study involved outpatients diagnosed with major depressive disorder. Participants were randomly assigned to receive either:
- NCAT-D combined with SSRIs (57 patients)
- SSRIs with a control treatment (61 patients)
Key Findings
After 12 weeks, the results showed:
- The NCAT-D and SSRIs group had a significantly greater improvement in cognitive function compared to the control group.
- There was a notable reduction in depression scores for the NCAT-D group.
- No significant difference in side effects was observed between the two groups.
Conclusion
Combining NCAT-D with SSRIs is effective and well-tolerated for patients with LLD and cognitive impairment.
Trial Registration
Registered on October 18, 2022, at ClinicalTrials.gov (Identifier: #NCT05588102).
Practical Solutions for Healthcare
Clinical trials play a vital role in creating safe and effective treatments. To make these benefits accessible in everyday practice, we offer DocSym, an AI-driven platform that:
- Consolidates ICD-11 standards, clinical protocols, and research into one easy-to-use resource for clinicians.
- Streamlines operations with mobile apps for scheduling, treatment monitoring, and telemedicine.
Enhancing Patient Care
By utilizing AI, clinics can improve workflows, enhance patient outcomes, and reduce paperwork. Discover more about how we can assist at aidevmd.com.
